

Research Roundup – advancing the publishing of pharmaceutical industry research

MedComms Networking Brunch 21 October 2019




Disclosures

 Chris Winchester is an Employee and Director of Oxford PharmaGenesis Ltd, a Director and Shareholder of Oxford PharmaGenesis Holdings Limited and a Director of Oxford Health Policy Forum CIC


Lack of trust in vaccines is causing needless suffering and death





Lack of trust in vaccines is causing needless suffering and death





Focus on France

- Has the lowest confidence in vaccine safety in the world
- Measles vaccination rates have fallen to 85% (below the 95% needed)
- > 2500 cases of measles in the year to May 2018
- 22% admitted to hospital
- 3 deaths, most recently an immunocompromised 17-year-old girl

Italy, Greece and Bulgaria are also suffering severe epidemics

Lack of trust in statins is causing needless suffering and death



In the UK, 218 971 people stopped taking statins in the 6 months after [adverse] media coverage, which could potentially be associated with

2173–6372 excess CV events

in the following 10 years (assuming a 66–0% restart rate)




The same trends have been seen in Denmark, Netherlands, Turkey and Australia

CV. cardiovascular

Matthews A et al. BMJ 2016;353:i3283; Nielsen SF et al. Eur Hear J 2016;37:908–16; Schaffer AL et al. MJA 2015;202:591–5; Kocas C et al. Int J Cardio 2015;201:139; van Hunsel et al. Br J Clin Pharmacol 2009;67:558–64; Images: https://www.bmj.com/content/353/bmj.i3283; https://www.theguardian.com/society/2014/mar/21/-sp-doctors-fears-over-statins-may-cost-lives-says-top-medical-researcher (Accessed 11 January 2019)









Agenda

Time	Topic	Speaker
10:30	Introduction	Chris Winchester, Oxford PharmaGenesis
10:40	Disclosing the results of clinical trials: how is the pharmaceutical industry doing?	Gemma Rogers, Oxford PharmaGenesis
11:05	Good Practice for Conference Abstracts and Presentations: GPCAP	Jackie Marchington, Caudex
11:30	Professional medical writers increase the quality and speed of clinical trial reporting	Obaro Evuarherhe, Oxford PharmaGenesis
11:55	Open access policies of leading medical journals: a cross-sectional study	Tim Ellison, Oxford PharmaGenesis
12:20	Open Pharma position statement on open access	Chris Winchester, Oxford PharmaGenesis
12:30	Meeting close	